June 19, 2014 7:57 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
In a report published Thursday, MLV & Co. analyst Arlinda Lee initiated coverage on
Sorrento Therapeutics (NASDAQ: SRNE) with a Buy rating and $9.00 price target.In the report, MLV & Co. noted, “We are initiating coverage of SRNE with a Buy rating and $9 price target. We believe that lead product candidate Cynviloq, a next generation paclitaxel, has a 75% chance of showing bioequivalence to CELG's Abraxane (CELG – $-159.94 - not covered), gaining FDA approval, and capturing 25% of the addressable paclitaxel market. Second product candidate resiniferatoxin (RTX), a non-opioid severe pain drug, also contributes to our probability-adjusted valuation.”Sorrento Therapeutics closed on Wednesday at $5.62.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.